It is unclear how the immune response controls human herpes virus 8 (HHV8; also known as Kaposi's sarcoma-associated herpesvirus KSHV) replication and thereby prevents Kaposi sarcoma (KS). We compared CD8 T cell responses to HHV8 latent (K12) and lytic (glycoprotein B, ORF6, ORF61, ORF65) antigens in patients who spontaneously controlled the infection and in patients with post-transplant, AIDS-related or classical KS. We found that anti-HHV8 responses were frequent, diverse and strongly differentiated towards an effector phenotype in patients who controlled the infection. Conversely, HHV8-specific CD8 cells were very rare in patients who progressed to KS, and were not recruited to the tumoral tissue, as visualized by in situ tetramer staining of KS biopsies. Lastly, HHV8-specific CD8 T cells were observed in a seronegative recipient of HHV8-infected graft who remained persistently aviremic and antibody-negative, suggesting that specific CTL may provide protection from persistent HHV8 infection. These results support the crucial role of cellular immune responses in controlling HHV8 replication, in preventing malignancies in latently infected subjects, and in conferring genuine resistance to persistent infection. They may also have important implications for the design of prophylactic and therapeutic HHV8 vaccines, and for adoptive immunotherapy of KS.
Introduction
HHV8, a lymphotropic γ herpes virus, is identified as the causative agent of Kaposi sarcoma 1 (KS), a vascular tumor containing proliferating spindle-shaped cells of endothelial origin (for review see 2, 3 ). KS is rare in immunocompetent individuals, but is the most common neoplasm in patients with AIDS who are not receiving highly active antiretroviral therapy (HAART). KS also occurs in immunosuppressed organ transplant recipients, and in some African populations (endemic KS) and Mediterranean populations (classical KS). The marked decline in the incidence of AIDS-related KS since the advent of HAART 4 , and the frequent resolution of transplant-related KS after reduction of immunosuppression 5 , highlight the key role of cellular immune responses in the control of HHV8 infection.
The nature of HHV8 proteins that are expressed by infected cells and permit their recognition by the immune system is unknown. HHV8 possesses a large genome with 90 open reading frames (ORF), of which 15 (K1 to K15) are unique to this virus. HHV8 latently infects endothelial cells and B lymphocytes, in which the viral episomes express only a limited number of genes. This implies that only a few viral peptides may be recognized by cytotoxic T lymphocytes (CTL) on latently infected cells. When immune control declines, infected cells may proliferate unchecked and HHV8-related tumors may develop. A proportion of infected cells undergo lytic viral replication, resulting in the production of infective virions. Viral gene expression is still markedly restricted in KS lesions, and lytic cycling is restricted to a small population of endothelial spindle cells 6 . HHV8-specific immune responses are poorly characterized. CTL targeting certain latent and lytic proteins have been generated in vitro [7] [8] [9] , but only a few CD8 T cell epitopes have been identified as immunogenic in short-term in vitro culture [10] [11] [12] [13] [14] [15] . Ex vivo CD8 T cell responses to HHV8 antigens have not been reported, except for glycoprotein B (gB) 13 . Almost half of the Caucasian population is HLA-A2. Studying T cell responses in HLA-A2+ individuals is therefore not only convenient, but also highly relevant for the design of peptide vaccine trials. To further characterize cellular anti-HHV8 responses, we first identified potential HLA-A2-restricted CD8 epitopes of selected latent (K12) and lytic (gB, ORF6, ORF61, ORF65) proteins. Using a panel of HLA-A2 tetramers specific for these epitopes, we then quantitatively and functionally assessed HHV8-specific circulating CD8 T cells in a cohort of HLA-A2+ infected patients with and without KS, and we directly visualized virus-specific CD8 T cells infiltrating KS lesions by in situ tetramer staining. We obtained new information on the specificity, magnitude and functionality of HHV8-specific responses, that should help to identify markers of immune protection and to develop more effective vaccines.
Patients and Methods

Patients
Written informed consent was obtained from each patient, and the study protocol was approved by the ethics Committee of Hôpital Saint-Louis (Paris, France). Peripheral blood mononuclear cells (PBMC) were collected, separated by Ficoll gradient centrifugation (Eurobio), and cryopreserved for later analysis. We studied forty-eight HLA-A*0201-positive HHV8-infected patients, comprising 12 HIV-seronegative kidney transplant recipients (mean age, 53 years), 24 patients with AIDS-related KS (mean age, 47 years) and 12 patients with classical KS (mean age, 61 years). The transplant recipients were all receiving conventional immunosuppression (azathioprine, methylprednisolone and cyclosporine) and included 8 patients without KS, 2 patients with ongoing KS, and 2 patients in remission from KS after a reduction of immunosuppression. The AIDS patients were all on HAART, and comprised 7 patients with ongoing KS and 17 patients in remission, of whom 6 had completed chemotherapy for KS at least 6 months before study. The patients with classical KS comprised 9 patients with ongoing KS and 3 patients in remission, of whom 2 had received chemotherapy. Patients with transplant-related or classical KS had isolated cutaneous involvement, whereas 9 patients with AIDS-related KS had visceral involvement in addition to cutaneous involvement. We also studied two HHV8-negative transplant recipients whose donors were HHV8-infected. Immunofluorescence assay was used to detect LANA antibodies and ELISA was used for K8.1 antibodies. HHV8 DNA load was determined by real-time PCR in PBMCs, as described elsewhere 16 . The positivity was defined as the linearity of 50 to 1000 000 copies/150 000 cells for 50 µl of reaction volume (detection threshold corresponding to 10 copies/150 000 cells). Controls consisted of PBMC from 8 HLA-A2+ healthy donors and 18 HLA-A2-negative HHV8+ individuals. HLA-A2 typing was performed by flow cytometry on PBMCs using the HLA-A2-specific BB7.2 monoclonal antibody (American Tissue Cell Culture, ATCC), and was confirmed by sequence-specific primer amplification (HLA-A2 PCR-SSP,Dynal).
Peptides and HLA-A2 stabilization assay
Peptides were synthesized by NeoSystems (Strasbourg, France). TAP-deficient T2 cells (American Type Culture Collection ATCC, Rockville, Maryland, USA) were grown for 18 hours at 37°C in serum-free medium, then 10 6 T2 cells were pulsed with 10 µM peptide in the presence of 20 µg/ml β2 microglobulin (Sigma) and 10 µg/ml brefeldin (Sigma) for 18 h at 37°C. After washing, cells were stained with the HLA-A2-specific BB7.2 antibody (American Tissue Culture Collection), and then with PE-conjugated goat anti-mouse Ig. HLA-A2 expression was measured with a FACSCalibur TM flow cytometer. The fluorescence index was calculated as follows: FI = (mean fluorescence intensity with peptide -mean fluorescence without peptide)/ mean fluorescence without peptide.
MHC class I tetramers, antibodies and flow cytometry
HLA-A2 tetramers were produced as described elsewhere 17 . Each tetramer was titered individually, and used at the optimal concentration (5-10 µg/ml). For staining, 10 6 PBMCs were incubated at 37°C for 30 min in the dark with 0.5-1.0 µg of PE-labeled tetramer, then with a combination of the following antibodies: CD8-APC (Caltag), CD3-FITC (BD/Pharmingen), CD45RA-PerCP (Beckman/Immunotech), and CCR7-FITC (R&D) or CD27-FITC (BD/Pharmingen) for 15 minutes at 4°C. Small lymphocytes were gated according to forward/side scatter profiles, then CD3+CD8high cells were selected, and staining with 7AAD (PharMingen) was used to exclude dead cells. Data were collected on a FACSCalibur TM flow cytometer within one hour after staining, and were analyzed with Cell Quest software (Becton-Dickinson). To determine nonspecific tetramer staining of peripheral CD8 T cells, a series of 18 HLA-A2-negative/HHV8+ individuals were analyzed, yielding a lower detection limit for positive staining in A2+/HHV8+ individuals (cutoff = mean frequency of tetramer+ cells in A2-/HHV8+ subjects + two times the standard deviation (SD)). For intracellular perforin staining after tetramer and CD8 staining, cells were fixed for 10 minutes in 2% paraformaldehyde solution, then washed, permeabilized in 2% saponin solution and stained with perforin-FITC antibody (Pharmingen).
In situ tetramer staining Biopsies of cutaneous lesions were available in 2 patients with classical KS. Parts of the samples were taken for diagnostic evaluation, while other parts were frozen for later in situ tetramer staining. Sections (5 µm) were cut and fixed in acetone for 10 minutes at room temperature. Nonspecific binding sites were blocked for 30 minutes with 40% BSA-5% FCS in PBS, followed by the Biotin-Blocking System (Dako) and washing with PBS. Sections were stained overnight at 4°C with Cy3-labeled HHV8-tetramers (10 µg/ml diluted in 2% fetal calf serum in PBS). Sections were washed 3 times for 10 minutes in PBS with 0.5% Triton X-100 (Sigma), and incubated for 1 hour at room temperature with rat anti ORF-73 of HHV8 (Tebu-Bio) diluted 1:1000. After 3 washing steps with PBS, sections were incubated for 45 minutes with FITC-conjugated goat anti-rat (1/100 diluted, Jackson Laboratories). After washing, sections were then incubated for 90 minutes at 4°C with mouse anti-human CD8 (1/75 diluted, clone DK25, DakoCytomation), washed 3 times and incubated for 40 minutes with Cy5-conjugated goat anti-mouse (1/50 diluted, Jackson Laboratories). Slides were mounted in Vecta shield medium (Vector Laboratories) and analyzed by confocal laser scanning microscopy (Leica). Cells were analyzed in a minimum of 50 Z stacks per skin section by an operator who was unaware of the clinical data. Images were acquired with a x63 objective and analyzed with Image J software (http://rsb.info.nih.gov/ij).Each experiment included a sample taken from a KS-HLA-A2+ patient for diagnostic purpose, as negative control.
Statistical analysis
The chi-square test was used to compare the number of patients with tetramer-positive response in the different groups. The non parametric Mann-Whitney rank sum test was used to compare frequencies between groups. When three or more unpaired groups were compared, the Kruskall-Wallis test was used, and Dunn's post test was used to narrow down which group was significantly different from the others. Statistical difference was assumed when p (two-tailed) was <0.05.
Results
Identification of HLA-A*0201-binding HHV8-derived epitopes
To identify HHV8-specific CD8 T cells, we selected potential HLA-A*0201-restricted CTL epitopes from latent and lytic proteins. Among them, threeepitopes, derived from one latent antigen (K12 [17] [18] [19] [20] [21] [22] [23] [24] [25] ) and two lytic antigens (gB 492-500 and K8.1 209-217 ) have previously been described as immunogenics 10, 14 . In addition, we attempted to identify epitopes of the latencyassociated nuclear antigen (LANA), and the lytic proteins ORF65, ORF6 and ORF61. LANA is responsible for persistence of the episomal genome and is detected in all HHV8-infected cells. ORF65 is a small viral capsid component that can be used to measure humoral immunity, suggesting it can also give rise to T cell responses. ORF6 (ssDNA binding protein) and ORF61 (large ribonucleotide reductase subunit) were chosen because immunodominant CTL epitopes have been described in the corresponding ORFs of the murine herpes virus MHV-68 γ 18 . To identify potential CTL epitopes within these proteins, their amino acid sequences were analyzed by computer algorithms designed to predict HLA-A*0201 binding peptides, based on the estimated half-time dissociation of the HLA-peptide complex (wwwbimas.dcrt.nih.gov) or prediction of MHC class I ligands (syfpeithi.bmi-heidelberg.com). Selected peptides (Table 1 ) were synthesized, and tested for HLA-A2 binding in a conventional HLA-A2 stabilization assay with the mutant T2 cells( Table 1 ). The reference high-binder peptide CMV-pp65 which bound efficiently to T2 cells, with an index of fluorescence intensity of 3.9,was used as a positive control in all experiments. Tetramers of K12, gB, ORF6, ORF61, ORF65 peptides were generated. The K8.1 peptide did not bind to HLA-A2 and did not permit refolding of HLA-A2 monomers, and may not therefore be an HLA-A2-restricted T-cell epitope. Altogether, there was a good correlation between the capacity of a given peptide to bind HLA-A2 molecules on T2 cells, its ability to generate large amounts of stable tetramers, and the peptide binding score determined by a HLA class I ligand prediction computer programs.
The frequency, magnitude and diversity of HHV8-specific responses depend on the clinical setting
A series of 18 HLA-A2-negative individuals were analyzed for each tetramer, allowing us to define a detection limit for positive staining in A2+ individuals (cutoff = mean frequency of tetramer+ cells in A2-negative subjects + 2 SD; Table 2 ), as described in (Pittet JEM 1999 , et Gannage 2005 .Using these cutoffs, we did not detect HHV8 tetramer+ CD8 T cells in 8 HLA-A2+ healthy blood donors (data not shown). Using the pp65 CMV tetramer as positive control, we found specific CD8 T cells in all HLA-A2+ CMV-seropositive healthy subjects (mean 1.40%, range 0.05% to 6.3%). The frequency and diversity of HHV8-specific CD8 T cell responses in 48 HHV8-infected patients is shown in Table 2 . Positive responses to at least one latent or lytic HHV8 epitope were detected in 67% of patients, with tetramer+ cell frequencies ranging from 0.16% to 2.2% of CD8 T cells. A mean of two HHV8 peptides were recognized per patient. These results indicate that anti-HHV8 CD8 T cell responses are frequent in infected individuals, and show their diversity and lack of immunodominance. Responses to the CMV-pp65 peptide were detected in 76% of patients (0.24-16.3% of CD8 T cells). As the context in which HHV8 infection occurred was not the same among the different patients, we examined whether HHV8-specific CD8 responses varied by comparing transplant recipients, patients with AIDS-related KS and patients with classical KS. HHV8-specific T cell responses were less frequent in AIDS-related KS than in transplant recipients or patients with classical KS (Figure 1a) . Moreover, responses in AIDS-related KS were of lower magnitude ( Figure 1b ) and diversity: a mean of 0.96 HHV8 peptides were recognized per HIV-infected patient, compared to 2.5 peptides in patients with classical KS and 3.4 in transplant recipients (p<10 -4 ). To ensure that the weak responses in HIV-infected patients were not related to a general weakness of anti-viral T cell immunity, we measured HIV-and CMV-specific responses by using relevant tetramers. Responses to the HLA-A*0201-restricted HIV gag epitope were low, as expected in patients on HAART. However, responses to the immunodominant pp65 peptide of CMV were strong in more than 80% of patients (0.5-6.3% of CD8 T cells) 19 . Likewise, the weak HHV8-specific response was not associated with HIV-related CD4 T cell depletion, as 55% of patients with CD4 cell counts of more than 200/mm3 had no responses, compared to 33% of patients with counts below this value (p= 0.61, Fisher's exact test). The HIV-infected patients were younger than the transplant recipients and the patients with classical KS (p= 0.005), indicating that weak anti-HHV8 responses were not related to an age-associated decline in virus-specific T cell responses. Together, these results show that patients with AIDS-related KS have a lower capacity to mount anti-HHV8 responses than transplant recipients and patients with classical KS.
HHV8-specific responses are impaired in patients who progress to Kaposi sarcoma
As the course of HHV8 infection was not the same among the different groups of patients, we examined whether HHV8-specific responses could influence the progression of viral infection, by grouping the patients according to the absence or presence of KS. The first group was composed of 8 transplant recipients who were HHV8-seropositive at the time of grafting but remained consistently PCR-negative and did not develop KS after a mean followup of 24 months. They were compared to 40 patients who progressed to KS (4 kidney transplant, 12 classic KS and 24 AIDS-related KS patients). The patients who did not develop KS had more frequent anti-HHV8 T cell responses than the patients who developed KS, while the frequency of CMV-specific responses was similar in the two groups (Figure 1c) , suggesting that these differences did not reflect global CD8 T cell dysfunction in the KS patients. In addition, the patients who did not develop KS had a broader repertoire of HHV8-specific responses than the patients who progressed to KS: a mean of 3.6 and 1.6 HHV8 peptides, respectively, were recognized per patient (p= 0.007, non parametric ANOVA). Although age is an established risk factor for KS, the patients with KS were not older than the patients without KS (52 and 54 years, respectively). These data suggest that multiepitopic HHV8-specific CD8 T cells contribute to HHV8 control and to protection from KS. However, because patients who did not develop KS were all transplant recipients, it cannot be excluded that their higher frequency of HHV8-specific response is due to the clinical context in which HHV8 infection occurred. Indeed, our preliminary results in a series of HIV+ HHV8+ KSpatients showed weak HHV8-specific CD8 T cell responses, of the same order of magnitude that responses observed in HIV+ KS+ patients (supplementary Table) , suggesting that HIV infection by itself may be deleterious for HHV8 response. Patients with KS were further subdivided into those (n= 22) who were in remission from KS and who had undetectable HHV8 viral load for at least 6 months at the time of the study (mean length of remission 57 months), and those (n= 18) with persistent KS lesions. Anti-HHV8 CD8 T cell responses were more frequent in patients with persistent lesions than in patients in remission. There was no correlation between the frequency of HHV8-specific responses and the duration of KS remission.
HHV8-specific CD8 T cells are functionally relevant
To determine whether the observed differences in the magnitude and diversity of HHV8-specific responses were functionally relevant, we characterized the phenotype of CD8 T cells directed against the predominant epitope(s), i.e. the epitope(s) associated with the highest percentage of tetramer+ cells in each patient. Significant differences in the extent of CD45RA, CD27 and CCR7 positivity among HHV8-tetramer+ cells were found between transplant patients without KS, patients in remission from KS, and patients with ongoing KS (Figure 2a) . We observed strong polarization towards a late CD45RA+/CCR7-or CD45RA+/CD27-phenotype in transplant patients who spontaneously controlled HHV8 infection compared to patients with ongoing KS and patients in remission. Conversely, transplant patients who spontaneously controlled HHV8 infection had lower percentages of early/intermediate differentiated CD8 T cells expressing a CD45RA-/CCR7-phenotype (Figure 2b ). There were no differences according to whether cells responded to latent or lytic HHV8 epitopes. CMV tetramer+ cells were predominantly late differentiated effector cells (not shown). Of note, there was no correlation between HHV8 viral load and the number or differentiation phenotype of tetramer+ cells. We then studied the relationship between the memory cell phenotype and perforin expression, which reflects immediate effector function (Figure 2c ). Perforin levels were variable in terms of both the number of perforin-expressing tetramer+ cells and the staining intensity (low to high perforin content). However, we observed more perforin-expressing tetramer+ cells in patients without KS than in patients with KS. Thus, although their cytotoxic efficiency may vary, HHV8-specific CD8 T cells exhibit effector functions and may thus control progression to KS.
In situ visualization of HHV8-specific CD8 T cells
To determine whether low frequency of HHV8-specific CD8 T cells in the peripheral blood of patients with KS is secondary to their specific migration within the tumor, we used in situ tetramer staining and confocal laser scanning microscopy to analyze KS biopsy specimens taken from 2 patients who had detectable circulating HHV8-specific responses at the same time. Large tetramer-negative CD8 T cell infiltrates were observed in the vicinity of LANApositive infected cells (Figure 3) . However, only very few CD8 T cells exhibited costaining with HHV8 tetramers, and these tetramer+ cells did not colocalize with tumor cells, but were scattered among LANA-negative areas. A control biopsy, performed in a KS-HLA-A2+ patient for diagnostic purpose showed no staining with the tetramers (not shown). This indicates that HHV8 epitope-specific CD8 T cells are not recruited within inflamed tumoral tissue, which may at least in part explain the lack of T cell-mediated tumor immunity in KS patients.
CD8 T cell phenotype shifts following changes in viral load and clinical events
To determine the functional relevance of HHV8-specific T cells in vivo, we studied their changes over time, with respect to clinical events and viral load changes, in a transplant recipient who presented recurrent remission/relapse episodes of KS lesions (UPN11, Figure  4 ). Three-to six-fold expansions of both lytic and latent HHV8-tetramer+ cells were observed over periods of about 3 months, and these changes coincided with HHV8 viral load negativization and complete regression of KS lesions. More than 90% of these expanded HHV8-specific T cells had a late effector cell phenotype and abundantly expressed perforin. After a few months of clinical remission, viral load rebounded (except at month 8 where it was still undetectable), tetramer+ cell numbers fell, and KS lesions relapsed. Although restricted to one case, these data indicate that rapid variations in HHV8-specific CD8 T cell numbers may result from antigen-specific cell proliferation due to viral reactivation. This also indicates that HHV8-specific CD8 T cells participate in the control of KS lesions.
HHV8-exposed but uninfected individuals can mount specific CD8 T cell responses
As primary HHV8 infection is usually asymptomatic, it is difficult to follow initial immune responses to the virus. We were able to examine two HLA-A2+ HHV8-seronegative patients who received kidney grafts from HHV8-infected donors. Both recipients remained consistently aviremic and antibody-negative, for 24 and 11 months after grafting, respectively. Interestingly, HLA-A2-restricted HHV8-specific tetramer+ cells were found in the recipient who received a graft from an HLA-A2-positive donor (Figure 5a ), while no response was detected in the other recipient, whose donor was A2-negative. The presence of tetramer+ cells specific for all lytic epitopes in the first recipient suggests that viral replication at very low levels, below those detected by current assays, primed the immune response. As most tetramer+ cells were phenotypically characterized as late effector cells expressing perforin (Figure 5b,c) , it is likely that the generation of HHV8-specific CTL can lead to abortive infection. Furthermore, the absence of detectable responses in the recipient with an HLA-A2-negative donor suggests that HHV8-specific CD8 T cells are restricted by donor HLA alleles. Therefore, the presence of specific CTL may provide protection from persistent HHV8 infection.
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Discussion
Several viruses, such as EBV, CMV, and HCV can establish persistent infection, their replication being tightly controlled by specific CTL [20] [21] [22] . Immune responses to HHV8, the most recently identified human herpes virus, are far less well documented. Our results indicate that HLA-A2-restricted HHV8-specific CTL can both abort the primary infection and control the latent infection, thereby protecting the host from progression to KS. As almost half of the Caucasian population is HLA-A2, these observations have strong implications for the design of prophylactic and therapeutic vaccine strategies.
We found that HHV8-infected subjects generated polyclonal CD8 T cells targeting a variety of viral proteins. Lytic (gB, ORF6, ORF61, ORF65) or latent (K12) antigen-specific cells were detected in more than two-third of patients, and together could account for up to 8% of the circulating CD8 pool. The magnitude, diversity and functional capacity of these cells varied however, according to the clinical context (circumstances and outcome of primary infection). HHV8-specific CD8 T cells were more frequent and more diverse in patients who controlled HHV8 infection than in those who progressed to KS. Moreover, we observed a marked enrichment of late effector cells with cytotoxic potential in HHV8+ transplant recipients who did not progress to KS, whereas patients with AIDS-related or classical KS showed a substantial enrichment in cells with an earlier phenotype and weak cytotoxic potential. As the HHV8+ transplant recipients remained free of KS for at least 2 years after grafting, it is likely that they will never develop KS 23 . If resistance to KS is indeed mediated by HHV8-specific CTL, then the protection they confer seems to last long enough to avoid tumor development during the first months after grafting, when immunosuppression is maximal. A kinetic analysis of a transplant recipient with relapsing KS further confirmed the functionality of antiviral CTL in vivo. Indeed, a fall in the frequency of HHV8-specific CD8 T cells coincided with viremic rebound and with clinical relapse.
Why were HHV8-specific responses impaired in some patients? As HAART also controls HHV8 replication 24 , anti-HHV8 responses might wane over time in patients on HAART who enter remission from KS, in keeping with the dependency of specific CTL on continued viral replication 25 . In a recent study, responses to ORF73 and ORF65 were observed in HIV-coinfected patients with active KS and elevated HHV8 load, but whether the detected responses were CD4-or CD8-mediated was not known 26 . We found here that HHV8-specific responses could persist in transplant recipients at relatively high levels in the absence of detectable circulating virus. Therefore, it is likely that HIV infection itself impairs cellular responses to HHV8. Indeed, our preliminary results in HIV+ HHV8+ KS-patients showed weak HHV8-specific CD8 T cell responses, which support this hypothesis. The reason for the weak responses observed in patients with classical KS is more puzzling, but may relate to differences in the route of antigen exposure 27 . Saliva is the source of most infections in endemic areas,. KS in transplant recipients is primarily due to virus reactivation, but de novo infection by the allograft has also been described. As HHV8 load (DNA copies) is higher in saliva than in blood or semen, the distinct patterns of CD8 T cell differentiation observed here might reflect route-and inoculum-dependent differences in the nature or efficiency of antigen processing, or in the repertoire of CD8 T cells that interact with antigen-presenting cells at the site of priming. In addition, HHV8-specific T cells might be prevented from exerting their antitumoral effector function by the multiple immunoregulatory strategies that KS cells use to avoid immune recognition, such as downregulation of MHC class I and costimulatory molecules [28] [29] [30] [31] [32] [33] . Such mechanisms could also explain the defect of migration and recruitment of virus-specific CTL to the tumoral tissue.
Of particular interest is the case of the transplant recipient who was exposed to HHV8 through the graft, and who had persistent HHV8-specific responses several months after grafting without developing detectable HHV8 infection. This patient may have had a very low level viral replication that primed the immune response, as observed recently in seronegative subjects who are at risk for HHV8 infection 26 and in persons who are repeatedly exposed to HIV or HCV but who do not seroconvert [34] [35] [36] , This case also raises a conceptual issue-how the HHV8-specific repertoire is shaped by donor MHC alleles. Recognition of the infected allograft may involve recipient-derived T cells either via HLA molecules shared with the donor, or through expansion of T cells that are solely restricted by the donor's HLA molecules. We found that this patient's HHV8 tetramer+ cells were apparently restricted by donor HLA molecules, as described in liver transplant patients recipients whose allograft is infected by HCV 37 . These HHV8 tetramer+ cells were not simply alloreactive cells, as they did not bind an irrelevant HLA-A2 tetramer containing HIV gag peptide (not shown). They were late effector cells, capable of invading peripheral tissues, including the infected graft. These findings support the hypothesis that an HHV8-infected graft is capable of stimulating and expanding naive recipient CD8 T cells, either directly via presentation of HHV8 antigens by infected B cells or endothelial cells, or indirectly via cross-presentation of HHV8 peptides by donor-derived dendritic cells. Whatever the mechanism, de novo acquisition of HHV8-specific CD8 T cells that mediate protection from persistent HHV8 infection in the recipient has major implications for HHV8 vaccine development and immunotherapy. It was recently shown that KS progenitor cells, which are thought to be infected by the virus, can be present in solid grafts and undergo neoplastic transformation in the recipient 38 , suggesting that KS tumor cells form continually in infected individuals but are suppressed or killed through normal immune surveillance. Our data strongly corroborate this idea.
In conclusion, although larger selection of patients with varied HLA types needs to be evaluated, our study highlights hitherto undescribed differences in CD8 T cell responses between patients who resolve or control HHV8 infection and patients who progress to KS. We confirm the crucial role of HHV8-specific CTL as effectors of long-term immune surveillance against a persistent virus, not only for controlling viral replication and preventing malignancies associated with latent infection, but also for generating genuine resistance to primary infection. This suggests that interventions aimed at controlling HHV8 infection should be started early. There is currently no way of predicting the individual risk of progression to KS in HHV8-infected individuals, and it will be interesting to see if anti-HHV8 responses could serve this purpose. Finally, our data support the use of vaccines or adoptive strategies to boost HHV8-specific CTL responses in patients with KS. § fluorescence index (FI) = (MFI with peptide-MFI without peptide)/(MFI without peptide) # Reference to the paper first describing the epitope. The HLA-A2-restricted CMV-pp65 and HIV-gag peptides were used as positive controls in CMVinfected and HIV-infeccted individuals, respectively. 
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